Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

4.16
Delayed Data
As of 2:59pm ET
 +0.19 / +4.79%
Today’s Change
1.83
Today|||52-Week Range
13.90
+114.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$37.7M

Company Description

Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. The firm distributes its products under the following brands: Treximet, Silenor, Zohydro ER with BeadTek, and Khedezla. The company was founded on March 9, 2010 and is headquartered in The Woodlands, TX.

Contact Information

Pernix Therapeutics Holdings, Inc.
10 North Park Place
Morristown New Jersey 07960
P:(800) 793-2145
Investor Relations:

Employees

Shareholders

Mutual fund holders3.86%
Other institutional14.71%
Individual stakeholders0.74%

Top Executives

John A. SedorChairman & Chief Executive Officer
Graham G. MiaoPresident, Chief Financial Officer & Director
Ken PiƱaChief Compliance Officer & General Counsel
Michael GolembiewskiVice President-Finance & Corporate Controller
Cindy LehrerVice President-Human Resources